Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;5(4):285-96.
doi: 10.2217/pmt.15.19. Epub 2015 Jun 19.

Mechanisms involved in the development of chemotherapy-induced neuropathy

Jessica A Boyette-Davis  1 , Edgar T Walters  2 , Patrick M Dougherty  3
Affiliations
Review

Mechanisms involved in the development of chemotherapy-induced neuropathy

Jessica A Boyette-Davis et al. Pain Manag. 2015.

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and painful condition seen in patients undergoing treatment with common agents such as vincristine, paclitaxel, oxaliplatin and bortezomib. The mechanisms of this condition are diverse, and include an array of molecular and cellular contributions. Current research implicates genetic predispositions to this condition, which then may influence cellular responses to chemotherapy. Processes found to be influenced during CIPN include increased expression of inflammatory mediators, primarily cytokines, which can create cascading effects in neurons and glia. Changes in ion channels and neurotransmission, as well as changes in intracellular signaling and structures have been implicated in CIPN. This review explores these issues and suggests considerations for future research.

Keywords: chemotherapy; cytokine; glial cells; ion channels; neuropathy; neurotransmission.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Schematic overview of mechanisms of chemotherapy-induced peripheral neuropathy
(A) Illustrates neuronal and glial targets for chemotherapeutics, including paclitaxel, bortezomib and oxaliplatin. (B) Indicates the mulitple ways these drugs alter neuron and glial cell function, resulting in activation of astrocytes, enhanced cytokine release, mitotoxicity and eventual apoptosis, spontaneous discharge and altered signaling in primary afferent fibers, and loss of cutaneous fibers, ultimately enhancing nociceptive input. CIPN: Chemotherapy-induced peripheral neuropathy; DRG: Dorsal root ganglion; ROS: Reactive oxygen species; TLR: Toll-like receptor; TRP: Transient receptor potential.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Boyette-Davis JA, Cata JP, Zhang H, et al. Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. J. Pain. 2011;12(9):1017–1024. - PMC - PubMed
    1. Bhatnagar B, Gilmore S, Goloubeva O, et al. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings. a single-center experience. Springerplus. 2014;3:366. - PMC - PubMed
    1. Cavaletti G, Bogliun G, Marzorati L, et al. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer. 1995;75:1141–1150. - PubMed
    1. Kroigard T, Schroder HD, Qvortrup C, et al. Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies. Eur. J. Neurol. 2014;21(4):623–629. - PubMed
    1. de Carvalho Barbosa M, Kosturakis AK, Eng C, et al. Quantitative sensory analysis of peripheral neuropathy produced by colorectal cancer and its exacerbation by cumulative dose of oxaliplatin chemotherapy. Cancer Res. 2014;74(21):5955–5962. - PMC - PubMed

MeSH terms